Table 1.
Non-coding RNAs that contribute to resistance or sensitivity to targeted therapy with BRAF or MAPK inhibitors.
| Induced Effect | Overexpression of ncRNAs | Target(s) | Drugs | References |
|---|---|---|---|---|
| Drug resistance | miR-34a, miR-100 and miR-125b | CCL-2 | Vemurafenib | [117] |
| miR-125a | BAK1, MLK3 | [118] | ||
| miR-204 and miR-211 | NUAK1/ARK5, IGFBP5, TGF-bRII, Slug, CHD5 | [119,120] | ||
| miR-514a | NF1 | [121] | ||
| MIRAT | IQGAP1/MAPK signalling | Trametinib (MEKi) and PLX4720 (BRAFi) | [126] | |
| SAMMSON | p32 mitochondrial protein | Vemurafenib and pimasertib (MEKi) | [81] | |
| EMICERI | MOB3B/LATS1/Hippo signalling axis | Vemurafenib | [127] | |
| Drug sensitivity | miR-7 | EGFR/IGF-1R/CRAF | Vemurafenib | [122] |
| miR-32 | MCL-1 | [123] | ||
| miR-200c | Bmi-1 | Vemurafenib or analog PLX4720 | [124] | |
| miR-579-3p | BRAF, MDM2 | Vemurafenib and trametinib | [125] |